Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said it completed its postmarketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities for pioglitazone-containing medicines, including diabetes drug Actos (pioglitazone HCl).